TOR Serine-Threonine Kinases
"TOR Serine-Threonine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
| Descriptor ID |
D058570
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.931 D12.776.476.925
|
| Concept/Terms |
TOR Serine-Threonine Kinases- TOR Serine-Threonine Kinases
- Kinases, TOR Serine-Threonine
- Serine-Threonine Kinases, TOR
- TOR Serine Threonine Kinases
- Target of Rapamycin Proteins
- Rapamycin Proteins Target
- mTOR Serine-Threonine Kinases
- Kinases, mTOR Serine-Threonine
- Serine-Threonine Kinases, mTOR
- mTOR Serine Threonine Kinases
- Mechanistic Target of Rapamycin Protein
- FK506 Binding Protein 12-Rapamycin Associated Protein 1
- FK506 Binding Protein 12 Rapamycin Associated Protein 1
- TOR Kinases
- FKBP12-Rapamycin Associated Protein
- Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Associated Protein
- Protein, FKBP12-Rapamycin Associated
- FKBP12-Rapamycin Complex-Associated Protein
- Complex-Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Complex Associated Protein
- Protein, FKBP12-Rapamycin Complex-Associated
- RAFT-1 Protein
- Protein, RAFT-1
- RAFT 1 Protein
- Rapamycin Target Protein
- Protein, Rapamycin Target
- Target Protein, Rapamycin
- mTOR Protein
- Protein, mTOR
|
Below are MeSH descriptors whose meaning is more general than "TOR Serine-Threonine Kinases".
Below are MeSH descriptors whose meaning is more specific than "TOR Serine-Threonine Kinases".
This graph shows the total number of publications written about "TOR Serine-Threonine Kinases" by people in this website by year, and whether "TOR Serine-Threonine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 6 | 6 |
| 2004 | 0 | 13 | 13 |
| 2005 | 0 | 13 | 13 |
| 2006 | 0 | 17 | 17 |
| 2007 | 0 | 28 | 28 |
| 2008 | 0 | 37 | 37 |
| 2009 | 1 | 35 | 36 |
| 2010 | 19 | 32 | 51 |
| 2011 | 22 | 16 | 38 |
| 2012 | 31 | 30 | 61 |
| 2013 | 27 | 23 | 50 |
| 2014 | 27 | 28 | 55 |
| 2015 | 26 | 29 | 55 |
| 2016 | 20 | 37 | 57 |
| 2017 | 13 | 22 | 35 |
| 2018 | 9 | 20 | 29 |
| 2019 | 10 | 16 | 26 |
| 2020 | 8 | 13 | 21 |
| 2021 | 7 | 6 | 13 |
| 2022 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles.
-
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 2022 10 01; 107(10):2295-2303.
-
Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget. 2022; 13:521-533.
-
The genetics of vascular birthmarks. Clin Dermatol. 2022 Jul-Aug; 40(4):313-321.
-
MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nat Commun. 2022 01 11; 13(1):245.
-
Costimulation of ?dTCR and TLR7/8 promotes Vd2 T-cell antitumor activity by modulating mTOR pathway and APC function. J Immunother Cancer. 2021 12; 9(12).
-
A gene toolbox for monitoring autophagy transcription. Cell Death Dis. 2021 11 02; 12(11):1044.
-
Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928.
-
Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. Cell Rep. 2021 08 03; 36(5):109491.
-
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 08 01; 204(3):312-325.
-
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. 2021 09; 40(37):5590-5599.